(HealthDay News) -- New research finds that the targeted cancer drug Tarceva nearly triples the amount of time lung cancer patients survive without a recurrence and has fewer side effects than standard chemotherapy.
The authors of a study appearing in the July 21 online issue of The Lancet Oncology recommend using Tarceva (erlotinib) as a first-line treatment for patients with advanced non-small-cell lung cancer who have the particular gene mutation this drug targets.
Other experts agreed.
"This is a very important study [because] it shows that we can identify patients with a specific genetic marker and direct specific treatment toward them," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. Read more...
Immunice for Immune Support
Many claims are being made about what one can do with Live Blood Analysis and this course will blow the trumpet of caution on several popular assumptions. That way you are going to end up with 1) a balanced view and 2) greater clinical confidence. By examining this topic in an comparative way from several angles you will get an excellent grasp of what is reasonable and above all what works in clinical practice!!
Subscribe to:
Post Comments (Atom)
Advanced Body Cleansing Kit$147.75 Advanced Body Cleansing Kit with Livatrex™, Oxy-Powder®, Latero-Flora™ and two bottles of ParaTrex®. |
No comments:
Post a Comment